Biomarkers /
MLLT4
Overview
Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog; Drosophila); translocated to, 4 (MLLT4; also known as AF6) is a gene that encodes a nectin- and actin-filament binding protein that functions as a component of an adhesion system and connects nectin to the actin cytoskeleton. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
MLLT4 is altered in 0.39% of all cancers with breast invasive ductal carcinoma, breast neoplasm, mixed lobular and ductal breast carcinoma, breast invasive lobular carcinoma, and colon adenocarcinoma having the greatest prevalence of alterations [3].
The most common alterations in MLLT4 are MLLT4 Amplification (5.08%), MLLT4 R1596H (0.21%), MLLT4 Loss (0.08%), MLLT4 Q1615dup (0.08%), and MLLT4 R1690W (0.41%) [3].
Clinical Trials
Significance of MLLT4 in Diseases
B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma And Classical Hodgkin Lymphoma +
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.